Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

“…We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects:

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Busulfan treatment induces orchitis. by Lingjun Zhao (21763122)

“…<p>(A) Hematoxylin and eosin staining of mouse testis tissue show gradual shedding of spermatogonia and decreases in the seminiferous tubule over time after busulfan treatment. …”

ASV and supplemental oxygen sleep treatments decrease fatigue and confusion. by Erica C. Heinrich (6832055)

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)